Quality Chemical bets on TB and sickle cell drugs

Quality Chemical Industries (QCI) is making significant investments in its manufacturing capabilities, with a $36 million expansion project currently in progress. The company is focusing on developing and producing treatments for tuberculosis and sickle cell disease. QCI aims to be the sole African producer of a new drug targeting these conditions, positioning itself to meet a critical unmet medical need on the continent.

This expansion and focus on specific diseases addresses significant health challenges in Africa, potentially improving access to essential medicines.